GlassScriptPhysician profile
Michael B Bradford
NPI 1346224920
$1,070.02
in general payments reported to CMS, 2019-2025
8 companies · $64.39 in 2025
The $64.39 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $307 · 2021: $289 · 2022: $150 · 2023: $70.69 · 2024: $86.58 · 2025: $64.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $221.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $557.32 | 2019-2022 | |
| Abbvie INC. | $153.74 | 2022-2025 | Durysta |
| Alcon Vision LLC | $106.50 | 2022-2024 | Rocklatan |
| Kala Pharmaceuticals, INC. | $87.16 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $71.28 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $41.80 | 2025 | Miebo, Vyzulta |
| Rxsight INC | $36.79 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Sun Pharmaceutical Industries INC. | $15.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bradford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.